文献速递肝胆胰外科围术期管理与 ERAS

医疗补助扩展对胰腺癌生存的影响

Impact of Medicaid Expansion on Pancreatic Adenocarcinoma Survival in the Southern US.
PubMed 文献 · J Am Coll Surg · 2026-03-26

本研究基于美国国家癌症数据库2008至2022年胰腺腺癌患者数据。研究发现,虽然胰腺切除术率保持稳定,但中位生存期显著改善,系统性治疗使用率上升;美国南部地区总生存期较差,医疗补助扩展受限与较差生存相关。

要点

  • 系统性治疗使用率从2008至2012年的68.9%升至2018至2022年的83.1%。
  • 南部患者总生存期23.7个月,低于东北部29.3个月、西部26.3个月和中西部25.3个月。
  • 医疗补助扩展受限与较差总生存独立相关(HR 1.12,95%CI 1.07–1.17,P<0.0001)。

核心结论

  • 胰腺切除术率未变,但总生存期显著改善,可能与系统性治疗使用增加有关。
  • 南部患者总生存期更差且接受系统性治疗的几率更低,提示医疗补助扩展受限可能驱动这些结局。

研究设计与样本

  • 使用美国国家癌症数据库识别2008至2022年胰腺腺癌患者。
  • 采用趋势分析评估治疗随时间的变化,并使用生存分析和逻辑回归。
  • 研究比较了美国不同地区(南部、东北部、西部、中西部)患者的结局。

主要发现

  • 胰腺切除术率保持稳定:2008至2012年19.7%,2013至2017年20.5%,2018至2022年19.8%(Cochran-Armitage趋势检验P=0.96)。
  • 手术患者中位生存期显著增加:2008至2012年20.7个月,2013至2017年25.6个月,2018至2021年31.1个月(Log-rank P<0.0001)。
  • 系统性治疗使用率显著增加:2008至2012年68.9%,2013至2017年76.7%,2018至2022年83.1%(Cochran-Armitage P<0.0001)。
  • 南部总生存期23.7个月,东北部29.3个月,西部26.3个月,中西部25.3个月(Log-Rank P<0.0001)。
  • 调整生存相关因素后,医疗补助扩展受限与更差总生存相关(HR 1.12,95%CI 1.07–1.17,P<0.0001)。

关键数值与推荐

  • 中西部患者接受系统性治疗的几率高于南部(OR 1.46,95%CI 1.39–1.54)。
  • 东北部患者接受系统性治疗的几率高于南部(OR 1.27,95%CI 1.20–1.34)。
  • 西部患者接受系统性治疗的几率高于南部(OR 1.14,95%CI 1.08–1.21)。
  • 南部总生存期23.7个月,东北部29.3个月,西部26.3个月,中西部25.3个月(Log-Rank P<0.0001)。

临床怎么用

  • 关注胰腺癌患者系统性治疗的可及性,尤其在美国南部医疗补助扩展受限地区。
  • 在临床实践中应积极评估并解决影响治疗可及性的政策与系统因素。
  • 对胰腺癌手术患者,应重视系统性治疗在改善生存中的作用。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Affordable Care Act and the Recalcitrant Cancer Research Act are health policies that can impact cancer survival. Of the 10 states that did not adopt Medicaid expansion, 7 are in the South. Here, we examine these policies' impact on pancreatic cancer treatment and survival. STUDY DESIGN: The National Cancer Database was used, identifying patients with pancreatic adenocarcinoma between 2008 and 2022. Trend analysis was conducted to evaluate changes in treatment over time. Survival analysis and logistic regression were used. RESULTS: The rate of pancreatectomy remained stable: 2008 to 2012: 19.7%; 2013 to 2017: 20.5%; 2018 to 2022: 19.8% (Cochran-Armitage Trend test: p = 0.96). Median survival for surgical patients significantly increased: 20.7 months in 2008 to 2012 vs 25.6 and 31.1 months in 2013 to 2017 and 2018 to 2021, respectively (Log-rank: p < 0.0001). Systemic therapy use significantly increased: 68.9% in 2008 to 2012 vs 76.7% in 2013 to 2017 and 83.1% in 2018 to 2022 (Cochran-Armitage: p < 0.0001). The overall survival (OS) was worse in the south, 23.7 months compared with 29.3, 26.3, and 25.3 months in the northeast, west, and midwest, respectively (Log-Rank: p < 0.0001). After adjusting for factors associated with survival, limited Medicaid expansion was associated with worse OS (hazard ratio: 1.12, 95% CI 1.07 to 1.17, p < 0.0001). Multivariable analysis showed that patients treated in the midwest (odds ratio [OR] 1.46, 95% CI 1.39 to 1.54), northeast (OR 1.27, 95% CI 1.20 to 1.34), and west (OR 1.14, 95% CI 1.08 to 1.21) had higher odds of receiving systemic therapy compared with the south. CONCLUSIONS: Although the rate of pancreatectomy did not change, the OS significantly improved during the study period, likely due to the increased use of systemic therapy. Patients in the south of the US had worse OS and lower odds of receiving systemic therapy, suggesting that limited Medicaid expansion police could have driven these outcomes.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Maegawa FB, Nguyen KT, Patel AD, et al. Impact of Medicaid Expansion on Pancreatic Adenocarcinoma Survival in the Southern US. J Am Coll Surg. 2026. PMID: 41532652. doi:10.1097/XCS.0000000000001761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。